{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:57:42Z","timestamp":1789927062858,"version":"4.0.1"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,10,24]],"date-time":"2004-10-24T00:00:00Z","timestamp":1098576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g\/m<jats:sup>2<\/jats:sup>) were retreated with high\u2010dose ifosfamide (HD\u2010IFX, 14 g\/m<jats:sup>2<\/jats:sup> per course), following relapse or development of a new bone tumor. The objective was to obtain responses and an improved event\u2010free survival (EFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>HD\u2010IFX was administered as described by Patel SR: <jats:italic>J Clin Oncol<\/jats:italic> 1997;15:2378. Efficacy of treatment was assessed initially after two to four courses. The interval between the courses was 3 to 4 weeks. Provided a response was obtained after two to four courses, treatment was continued for an additional eight courses unless progressive disease or an untoward event, for example, renal failure occurred. Tumor sites were: lung, (10) bone (9), and bone and soft\u2010tissue (1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Response after two to four courses was 62.5%: CR 6 and PR 4. A total of 84 courses were administered to the 16 patients: (range 2\u201310, median 5.5 per patient). Median interval between courses was 28.5 days (range 15\u201390). Five patients were disease free at 15+ to 63+ months after induction and maintenance therapy. Fever and neutropenia occurred in 12 courses. Nephrotoxicity was a major toxic event and was characterized by creatinine levels at or above three times the upper limit of normal. It was unpredictable and occurred in four patients: two were reversible. The other two patients developed full\u2010blown renal failure; one was treated with renal dialysis, but both eventually succumbed to osteosarcoma. Our past experience also indicated that two patients treated with IFX (9 g\/m<jats:sup>2<\/jats:sup>\/course) developed renal failure: one recovered and the other required a renal transplant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HD\u2010IFX is effective in patients who have failed conventional chemotherapy including IFX (9 g\/m<jats:sup>2<\/jats:sup>). Improved disease\u2010free survival was achieved in 30% of patients. However, renal failure constitutes an important life\u2010threatening complication and its development is unpredictable. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20228","type":"journal-article","created":{"date-parts":[[2004,10,25]],"date-time":"2004-10-25T17:53:57Z","timestamp":1098726837000},"page":"215-219","source":"Crossref","is-referenced-by-count":55,"title":["High\u2010dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity"],"prefix":"10.1002","volume":"44","author":[{"given":"Su G\u00fcls\u00fcn","family":"Berrak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semha","family":"Berbero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130nci Erg\u00fcrhan","family":"\u0130lhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,24]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"889","volume-title":"Principles and practice of pediatric oncology","author":"Link MP","year":"1997"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(75)80484-7"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<245::AID-CNCR7>3.0.CO;2-J"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606193142502"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C"},{"key":"e_1_2_6_7_2","first-page":"8","article-title":"Adjuvant chemotherapy of high\u2010grade osteosarcoma of the extremity. Updated results of the Multi\u2010Institutional Osteosarcoma Study","volume":"270","author":"Link MP","year":"1991","journal-title":"Clin Orthop"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089169207800311"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19911101)68:9<1899::AID-CNCR2820680909>3.0.CO;2-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512263132605"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.5.425"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1989.01410010132026"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850601)55:11<2653::AID-CNCR2820551121>3.0.CO;2-A"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/3.suppl_2.S7"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2614"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.8.1191"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2378"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(84)80189-6"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_23_2","first-page":"46","article-title":"Ifosfamide in pediatric malignancies","volume":"16","author":"Jurgens H","year":"1989","journal-title":"Semin Oncol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008361612767"},{"key":"e_1_2_6_25_2","first-page":"115","article-title":"High\u2010dose ifosfamide in advanced osteosarcoma","volume":"69","author":"Marti C","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_26_2","first-page":"131","article-title":"Phase II trial of ifosfamide in children with malignant solid tumors","volume":"71","author":"Pratt CB","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950240205"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3641"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.426"},{"key":"e_1_2_6_30_2","first-page":"2056","article-title":"Successful phase II trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group Trial (POG)","volume":"17","author":"Goorin AM","year":"1998","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00439-X"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199601)26:1<36::AID-MPO5>3.0.CO;2-W"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199901000-00004"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199902)32:2<93::AID-MPO4>3.0.CO;2-Y"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1600"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.1.170"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20228","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:30:38Z","timestamp":1696897838000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,24]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1002\/pbc.20228"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20228","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,24]]}}}